October 31, 2020

southmarstonplan

Business is the best

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Organization Improvement and Strategic …

TEL AVIV, Israel, Oct. 06, 2020 (Globe NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention Process (EPS) for the avoidance of stroke triggered by carotid artery disorder (CAD), now announced the appointment of Patrick Jamnik as vice president, small business improvement and strategic initiatives. In this recently established place, Mr. Jamnik will oversee the Company’s organization growth routines and enjoy a vital position in advancing its quick and very long-phrase strategic targets, with significantly of his target being the U.S. marketplace.

“At various moments through my career, I have been fortunate to see the strong effect produced when revolutionary technologies encounters legitimate unmet scientific requirements. CGuard™ EPS offers the option to create these an effect on the advancement of carotid artery stenting,” explained Mr. Jamnik. “I am thrilled to be signing up for InspireMD at this sort of an crucial and enjoyable time.”

Mr. Jamnik delivers with him a lot more than 15 many years of worldwide market place development expertise in broad-primarily based roles with both of those significant and emerging healthcare technological innovation companies. Prior to becoming a member of InspireMD, he served in a business management position for Stryker Corp. Before that, he served as director of worldwide promoting at Stanmore Implants Worldwide and played a central job in developing its U.S. business, contributing to its eventual acquisition by Stryker. Mr. Jamnik obtained both a BA and MBA from The College of Wisconsin-Madison.

“We welcome Patrick to the govt management group and search ahead to his leadership in advancing our growth by industry and portfolio enlargement alongside with strategic initiatives to make on the success of our CGuard EPS and Micronet system. As we acquire traction and leverage the exceptional scientific effects of our stent platform, we will go on to acquire new strategic pathways for advancement,” claimed Marvin L. Slosman, chief govt officer of InspireMD.

InspireMD also today declared that the Company has granted Patrick Jamnik, the Company’s new vice president of organization enhancement, 162,920 shares of restricted stock and alternatives to order 54,307 shares of the Company’s prevalent stock as inducement awards outside the Company’s 2013 Lengthy-Time period Incentive Program. The grant was permitted by the Payment Committee and was designed as an inducement product to the staff coming into into employment. The grant was made in reliance on the employment inducement exception to shareholder approval delivered under the NYSE American Company Manual, Part 711(a), which needs community announcement of inducement awards.

The possibility award has an workout price tag of $.34 per share, the closing price tag of the Company’s typical inventory on October 5, 2020, the grant date, and has a 10-yr time period. Equally the solution and limited stock awards will vest in a few equivalent installments on the to start with, 2nd, and third anniversaries of the date of grant, provided Mr. Jamnik remains employed by the Business as a result of the applicable vesting dates. These inducement awards also supply for accelerated vesting in relationship with a modify in control of the Organization or selected involuntary terminations of Mr. Jamnik’s work. 

About The CGuard® EPS

The CGuard® Embolic Protection System is an superior system resolution designed to deliver the adaptability of the standard open up-mobile stent with highly developed defense from peri-procedural and submit-procedural embolic activities brought on by plaque prolapse as a result of the stent strut that can direct to stroke. CGuard’s exclusive MicroNet® technologies mitigates the prolapse and associated embolization and has revealed exceptional clinical outcomes for people versus choice carotid stent types, standard and following-era double-layer stents, as perfectly as invasive processes these as endarterectomy, a key surgical method.  InspireMD’s CGuard™ has developed a new dimension in the secured treatment method of carotid artery condition and has the opportunity to create a new normal of treatment for the administration of carotid artery ailment and stroke prevention.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® know-how to make its items the sector regular for carotid stenting by supplying outstanding acute benefits and long lasting, stroke-cost-free, very long-expression outcomes.

Ahead-on the lookout Statements

This push launch has “forward-hunting statements.” These statements may well be preceded by the phrases “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar terms. Forward-looking statements are not guarantees of potential functionality, are centered on sure assumptions and are matter to many recognised and mysterious challenges and uncertainties, numerous of which are beyond the Company’s control, and can’t be predicted or quantified and for that reason, actual effects may possibly differ materially from individuals expressed or implied by these ahead-looking statements. This sort of hazards and uncertainties consist of, with out limitation, hazards and uncertainties connected with (i) sector acceptance of our current and new products and solutions, (ii) damaging clinical trial effects or lengthy merchandise delays in essential marketplaces, (iii) an incapability to safe regulatory approvals for the sale of our products, (iv) the effect of the COVID-19 pandemic on our producing, sales, company system and the world economy, (v) intense levels of competition in the medical device marketplace from substantially much larger, multinational providers, (vi) products liability statements, (vii) solution malfunctions, (viii) our confined manufacturing abilities and reliance on subcontractors for assistance, (ix) insufficient or inadequate reimbursement by governmental and other 3rd social gathering payers for our merchandise, (x) our efforts to correctly receive and keep mental property safety covering our products and solutions, which may possibly not be productive, (xi) legislative or regulatory reform of the healthcare program in each the U.S. and overseas jurisdictions, (xii) our reliance on solitary suppliers for sure product or service factors, (xiii) the actuality that we will need to have to elevate added funds to meet our business enterprise requirements in the potential and that these money increasing might be high priced, dilutive or challenging to receive and (xiv) the reality that we conduct business in a number of overseas jurisdictions, exposing us to foreign currency trade price fluctuations, logistical and communications worries, burdens and fees of compliance with overseas legislation and political and economic instability in just about every jurisdiction. A lot more thorough information about the Business and the threat components that may possibly have an affect on the realization of forward on the lookout statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Once-a-year Report on Type 10-K and its Quarterly Reviews on Variety 10-Q. Investors and stability holders are urged to read through these documents free of charge on the SEC’s internet internet site at https://www.sec.gov. The Business assumes no obligation to publicly update or revise its ahead-searching statements as a result of new details, long term occasions or normally.

Investor Contacts:

Craig Shore
Chief Money Officer
InspireMD, Inc.
888-776-6804
[email protected]